Search for: "Watson Laboratories Inc."
Results 101 - 120
of 177
Sort by Relevance
|
Sort by Date
18 Jul 2011, 5:16 pm
(“Cephalon”) on March 15, 2011 challenging FDA’s January 7, 2011 approval of Watson Laboratories, Inc. [read post]
17 Jul 2011, 9:17 pm
Watson Pharmaceuticals et al. 1:11-cv-00607; filed July 8, 2011 in the District Court of Delaware • Plaintiffs: Abbott Laboratories; Abbott Respiratory LLC • Defendants: Watson Pharmaceuticals Inc.; Watson Laboratories Inc. [read post]
15 Jul 2011, 11:32 pm
(IP Watch) (KEI) (Spicy IP) (GenericsWeb) Mucinex (Guaifenesin) – US: File history disclaimer dooms Reckitt Benckiser at CAFC: Reckitt Benckiser v Watson Laboratories / ?????? [read post]
15 Jul 2011, 11:32 pm
(IP Watch) (KEI) (Spicy IP) (GenericsWeb) Mucinex (Guaifenesin) – US: File history disclaimer dooms Reckitt Benckiser at CAFC: Reckitt Benckiser v Watson Laboratories / ?????? [read post]
11 Jul 2011, 9:59 pm
Watson Laboratories, Inc. - Florida, the Federal Circuit affirmed a decision by the District Court for the Southern District of Florida holding that Defendant-Appellee Watson Laboratories, Inc. - Florida did not infringe the asserted claims of U.S. [read post]
10 Jul 2011, 9:20 pm
• Defendants: Watson Pharmaceuticals, Inc.; Watson Laboratories, Inc.; Watson Laboratories, Inc. [read post]
8 Jul 2011, 1:13 pm
In 2009, Reckitt Benckiser Inc. sued Watson Laboratories, Inc. - Florida for patent infringement related to Watson's filing of three Abbreviated New Drug Applications for generic versions of Reckitt's Mucinex(R) line of products. [read post]
6 Jul 2011, 2:21 am
Biopet Vet Lab, Inc., et. al. [read post]
4 Jul 2011, 9:59 pm
• Defendants: Watson Laboratories Inc.; Watson Pharmaceuticals Inc.; Watson Pharma Inc. [read post]
22 Jun 2011, 4:09 am
A-G’s opinion published – Merck & Co Inc. v Deutsches Patent- und Markenamt (EPLAW) (The SPC Blog) US: Supreme Court to revisit patentable subject matter eligibility of medical diagnostic methods: Mayo v Prometheus (Patently-O) (Patent Baristas) (PharmaPatents) (IPBiz) (Patent Law Practice Center) US: Intellectual property problems for personalized medicine (BIOtechNow) US: Supreme Court ruling in Stanford v Roche (IPKat) (IPKat) US: Manager’s Amendment (and… [read post]
15 Jun 2011, 4:56 am
Watson Pharmaceuticals, Inc. et al. [read post]
9 Jun 2011, 10:16 am
Indianapolis, IN - Patent lawyers for Alcon Research Ltd of Fort Worth, Texas, Alcon Pharmaceuticals LTD of Switzerland, and Kyowa Haddo Kirin Co. of Japan filed a patent infringement in alleging Watson Laboratories Inc and Watson Pharma, Inc. of Parsippany, New Jersey, and Watson Laboratories, of Corona, California, infringed the following patent prior to the expiration: Patent No. 5,641,805, Topical ophthalmic formulations for treating… [read post]
9 May 2011, 6:07 am
Albers Medical, Inc., 395 F. [read post]
1 May 2011, 8:45 pm
• Defendants: Watson Pharmaceuticals Inc.; Watson Pharma Inc.; Watson Laboratories Inc. [read post]
12 Apr 2011, 9:37 pm
• Defendants: Watson Laboratories Inc.; Watson Pharmaceuticals Inc.; Watson Pharma Inc. [read post]
6 Apr 2011, 12:18 am
427/09 Generics (UK) Ltd v Synaptech Inc (The SPC Blog) Simcor (Niacin, Simvastatin) – US: Abbott files patent infringement complaint against Watson following Para IV certification filing (Patent Docs) Thalomid (Thalidomide) – US: Decision in Lannett Thalomid bioequivalence study sample antitrust lawsuit could reignite debate on generic drug availability and REMS restrictions (FDA Law Blog) Yasmin (Drospirenone, Ethinylestradiol) – UK: Bayer Yasmin patents survive… [read post]
28 Mar 2011, 9:59 pm
Watson Laboratories, Inc., the Federal Circuit reversed a decision by the District Court for the District of Nevada on summary judgment that the asserted claims of U.S. [read post]
27 Mar 2011, 9:28 pm
Watson Laboratories, Inc. [read post]
25 Mar 2011, 8:29 pm
Watson Laboratories (CAFC 2010-1331) insensibly nonprecedential Preliminaries to clobbering '969. [read post]
25 Feb 2011, 7:12 am
(collectively "Shire") have received a new Paragraph IV Notice Letter from Watson Laboratories, Inc. in Fort Lauderdale, Florida ("Watson") advising of the filing of an Abbreviated New Drug Application ("ANDA") for a generic version of all approved strengths of Shire's ADDERALL XR(R) (mixed salts of a single-entity amphetamine product) dextroamphetamine sulphate, dextroamphetamine saccharate, amphetamine aspartate monohydrate,… [read post]
